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Poster Session-II 133(cGVHD) was 54% and 34%, respectively. Probability of OS was
62% (CI95: 48.3–78.4). There was .10-fold interpatient variability
in AUC0-6 and MPA trough (C0). Mean PK are shown in Table 1.
Table 1. Mean pK Parameters
MMF PO MMF POIV MMF administration 1st sample 2nd sampleMean pK
valuesDay 11
(SD) [N527]Day 17
(SD) [N531]Day 114
(SD) [N532]Day 145-100
(SD) [N515]Day 145-100
(SD) [N59]Cmax (mg/L) 15.4 (19.71) 12.31 (7.99)
J 16.54 (13.24)J 13.15 (12.04) 13.20 (8.86)Tmax (h) 1.87 (0.47) 1.92 (0.55) 1.75 (0.44) 1.7 (0.98) 1.33 (0.83)C0 (mg/L) 0.33 (0.29)* 0.68 (0.56)* 0.72 (0.62) 1.45 (1.46) 1.43 (1.37)Css (mg/L) 5.45 (6.34) 4.73 (2.22) 6.46 (4.07) 5.38 (3.55) 6.54 (3.55)AUC0-6
(mgh/L)
32.06 (38.09) 26.82 (12.35)J 33.71 (16.86)J 26.50 (19.03) 26.70 (15.81)CLss (L/hkg) 1.46 (1.04) 1.40 (0.63) * 1.17 (0.63) * 2.21 (1.43) 1.46 (1.01)
Vss (L/kg) 3.04 (1.91) 3.35 (1.58)
l 3.00 (2.05)l 9.77 (8.93) 18.33 (35.74)T1/2 (h) 1.02 (0.69) 1.35 (1.01) 2.49 (6.77) 3.17 (2.63) 10.19 (18.06)*P50.002.
JP50.0003.
lP50.001
MPA steady state clearance (CLss) (cohort 1 vs 2 vs 3 5 1.65 vs
1.45 vs 0.88 L/h$kg, P 5 0.0039) and volume of distribution (Vss)
(cohort 1 vs 2 vs 3 5 3.87 vs 3.22 vs 2.44 L/kg, P 5 0.052) were
higher in pts\6 yrs. There was also a trend toward higher CLss in
pts receiving MA vs NMA (1.55 vs 1.15 L/h$kg, P 5 0.054). There
was a significant difference in most PK values on Day 17 vs Day
114: higher AUC0-6 & Cmax and decreased CLss & Vss on Day
114 (Table 1). These differences suggest improved mucosal healing
and/or increased enterohepatic recirculation on Day 114 vs 17.
Mean MPA Css in this study was significantly higher (.5 mg/L)
than previously reported in other adult and pediatric AlloSCT trials
(1.6–4.8 mg/L) (Nash et al, 2005; Jacobson et al 2008). This can be
explained by .2-fold higher dose of MMF (30 mg/kg q6h) com-
pared to others (15 mg/kg q6-8h). The incidence of aGVHD and
cGVHD were comparable to previous reports. These results suggest
a need for more frequent (q6h) MMF dosing in pediatric AlloSCT
recipients, especially those\6 years. However, the optimal MMF
dose (mg/kg) and relationship between MPA exposure and risk of
acute GVHD remain to be elucidated.371
HIGH BUDESONIDE BIOAVAILABILITY IN PATIENTS WITH GASTRO-
INTESTINAL (GI) GRAFT VERSUS HOST DISEASE (GVHD) AND/OR
CLOSTRIDIUM DIFFICILE INFECTION
Frame, D.G.1, Markstrom, D.1, Pogue, J.1, Yanik, G.A.2 1University of
Michigan, Ann Arbor, MI; 2University of Michigan, Ann Arbor, MI
Background: Therapy of acute intestinal GVHD is routinely
treated with immunosuppressive agents, including systemic cortico-
steroids. Several reports have shown responses of using ‘‘topical’’
therapy with budesonide for GI GVHD. Budesonide is a potent ste-
roid with low oral bioavailability due to high first pass metabolism by
CYP 3A4. In patients with Crohn’s disease, bioavailability is approx-
imately 10–20%. No data are available in hematopoeitic stem cell
transplant recipients. Several reports using budesonide for the treat-
ment of GI GVHD have noted responses in other GVHD sites, thus
questioning if active absorption was occurring. As a quality measure
at our center, several patients who had GI GVHD and/or C. Difficile
were evaluated for systemic availability of budesonide.
Methods: Random plasma budesonide levels were analyzed by
HPLC/Mass Spectrometry in 8 patients with a history of GI
GVHD receiving Enterocort brand of budesonide.
Results: A total of 11 budesonide plasma levels were measured in
8 patients. Seven patients had active GVHD, 5 patients had active
GVHD and concurrent C. Difficile infection, and 2 patients had
C. Difficile without active GVHD at the time of plasma measure-
ments. Four of the 8 levels were measured on a budesonide dose of
9 mg TID, two on 9 mg once daily, three on 6 mg TID, and twoon 3 mg TID. The mean budesonide plasma level was 0.86 mcg/dl
(0.08–1.5), 0.60 mcg/dl (0.09–1.1), 0.97 mcg/dl (0.2 – 1.1) and 0.65
mcg/dl (0.2–1.1) respectively. Mean budesonide levels were higher
if patients were on voriconazole (1.05 mcg/dl) than on micafungin
(0.47 mcg/dl). The mean budesonide bioavailability was 37% in all
patients and 50% if on Voriconazole. Thus, budesonide doses rang-
ing from 3 mg TID to 9 mg TID would represent a potency equiv-
alent to 40–162 mg methylprednisolone/day.
Conclusion: Systemic budesonide levels were significantly ele-
vated in patients with acute GI GVHD. Patients on voriconazole
had higher plasma levels of budesonide, possibly attributable to
CYP450 inhibition. The use of oral budesonide in patients with gas-
tro-intestinal GVHD may lead to systemic absorption and subse-
quent additive systemic corticosteroid effects.IMMUNE RECONSTITUTION372
THYMIC EPITHELIAL CELLS AND DENDRITIC CELLS MEDIATE THYMIC
RENEWAL THROUGH CCL25 PRODUCTION
Williams, K.M., Lucas, P.J., Bare, C.V., Wang, J., Mella, H.A.,
Gress, R.E. National Cancer Institute/NIH, Bethesda, MD
Impaired thymopoiesis contributes to immune deficiency follow-
ing hematopoeitic stem cell transplantation (HSCT). Clinical data
suggest that thymic epithelial cell (TEC) damage from the prepara-
tive regimen may compromise thymic recovery. We have previously
shown that TEC are critical for thymic renewal in the setting of an-
drogen withdrawal. These UEA1 medullary TEC provide a niche
for early thymic progenitor (ETP) entry and thymocyte development
by increasing the production of CCL25. Following androgen with-
drawal, CCL25 accelerates thymocyte development and enhances
ETP entry. Blockade of this ligand completely abrogates these af-
fects, preventing thymic renewal. We now demonstrate that cytotoxic
preparative regimens may impair thymic reconstitution by damaging
stroma, decreasing CCL25 availability. In this study, we examined
the effects of cyclophosphamide (CY) (240 mg/kg/mouse) or total
body irradiation in female mice on TEC and medullary dendritic
cell (mDC) populations and CCL25 production. At 1⁄2 myeloablative
dose of 750 cGy, using flow cytometry of TEC, we show that both CY
and radiation significantly deplete UEA1 medullary TEC while
sparing Ly511CD45- cells. However, the effects of these two agents
differed with regards to the proportions of TEC within the Ly511
fraction. Radiation led to an increase in fibroblasts (CD45- Ly511
MHCII-) with a marked reduction of cortical TEC (CD45- Ly511
MHCII1), while this TEC subset was spared following CY adminis-
tration. Furthermore, mDC were decreased following radiation
while unaffected by CY. After irradiation, these alterations signifi-
cantly impair CCL25 production as shown by decreased mRNA pro-
duction of TEC enriched preparations and thymocyte fractions (in
which only mDC produce CCL25). In contrast, CCL25 production
was unaffected following CY administration, consistent with the hy-
pothesis that the spared TEC populations preserve CCL25 produc-
tion. These data suggest that cytotoxic preparative regimens may
impair thymic renewal by destroying TEC and mDC populations
thereby reducing available CCL25, a ligand necessary and essential
for thymic recovery. Furthermore, these data suggest that different
preparative regimens may impair thymic recovery to varying degrees
due to discrimination of injured TEC and mDC populations, and the
preservation of thymic CCL25 production. Investigation of alterna-
tive preparative regimen agents may present an opportunity to im-
prove thymic renewal following HSCT.373
HUMAN COLON CARCINOMA CELLS EXPRESSING CMVPP65 ANTIGEN:
AN IN-VIVO MODEL FOR ADOPTIVE IMMUNOTHERAPY OF CMV DISEASE
Hasan, A.N.1, Koo, G.C.1, Selvakumar, A.1, Kollen,W.1, O’Reilly, R.J.1,2
1Memorial Sloan Kettering Cancer Center, New York, NY; 2Memorial
Sloan Kettering Cancer Center, New York, NY
Adoptive transfer of large doses of CMV-specific T cells (CMV-
CTL) can effectively prevent CMV disease in HSCT recipients.
However, data regarding the relative potency of T cells (TC) specific
134 Poster Session-IIfor different epitopes and the doses required to eradicate disease are
lacking. We have developed an in-vivomodel to assess specificity and
efficacy of CMV-CTL and establish TC doses required for treat-
ment using colon carcinoma cells transduced with CMVpp65 as
a surrogate system. HLA A02011 human colon carcinoma cells
transduced with CMVpp65 and GFP-firefly luciferase (CoCa-
pp65) were injected subcutaneously (s.c.) into NOD/Scid-IL2Rgc-
KO/J mice (NSG) at doses ranging from 104–106 (4 mice /group)
and tumor growth followed for 4 weeks using bio-luminescent imag-
ing and tumor measurements. Consistent engraftment was observed
with 3  105 cells. Groups of NSG mice were then injected s.c with
CoCa-pp65 (3  105) mixed with HLA A0201-restricted CMV-
CTL (A2-CMV-CTLs) at E:T ratios of 50:1, 10:1, 2:1 and 0.4:1.
To ascertain antigen specificity of A2-CMV-CTLs, groups of 4
NSG mice were subsequently co-injected s.c. with 3 tumor-TC
combinations (E:T 5 1:1) as follows: (i) A2-CMV- CTLs 1 3 
105 CoCa-pp65 (ii) A2-CMV- CTLs 1 A2 tumor without
CMVpp65 (iii) A2-Flu-CTLs 1 3  105 CoCa-pp65. Control ani-
mals were injected with the 2 tumors without TC. IL-2 (2000 U
i.p) was given 2  a week, growth followed by imaging x 4 weeks.
No growth of CoCa-pp65 was detected in any animal co-injected
with A2-CMV-CTL at any E:T ratio, with consistent tumor growth
over 4 weeks in controls. Current experiments are assessing E:T ra-
tios lower than 0.4:1. Tumor growth was observed in control groups
(ii) and (iii) with no detectable growth in (i) by imaging or examina-
tion of autopsied tissues. These studies demonstrate that CMV-
CTL can eradicate clonogenic tumor cells expressing an immuno-
genic viral antigen in-vivo at E:T ratios that are significantly lower
than those required in-vitro. This model also allows for comparison
of cytotoxic activity of TC directed against different immunogenic
epitopes and permits comparisons of virus-specific and tumor spe-
cific TC for their immunotherapeutic potential.374
OVERCOMING ANTIGENIC COMPETITION TO PRODUCE MULTISPECIFIC
CYTOTOXIC T LYMPHOCYTE LINES FOR ADOPTIVE TRANSFER
Leen, A.M., Christin, A., Gerdemann, U., Vera, J.F., Heslop, H.E.,
Brenner, M.K., Rooney, C.M. Center for Cell and Gene Therapy, Baylor
College of Medicine, The Methodist Hosptial, Texas Children’s Hospital,
Houston, TX
HSCT recipients are susceptible to lethal opportunistic infec-
tions, which are often not amenable to conventional therapies. We
have shown that adoptive transfer of just 2  105/kg in vitro ex-
panded multivirus-specific cytotoxic T lymphocyte lines (CTLs) tar-
geting EBV, CMV, and Adv can protect against these infections.
Within each CTL line, however, Adv-specific T cells were a minority
of the total. Furthermore, epitope analysis showed a small number of
Adv epitopes recognized by the trivirus lines, potentially limiting
their antiviral potency. This low frequency and restricted epitope
recognition is likely due to antigen/epitope competition and we
have now devised a means to overcome the problem so that we can
extend the approach to produce CTLs targeting additional viral
pathogens. We proposed that antigenic competition could be over-
come by promoting the survival of T cells with subdominant speci-
ficities using IL-4 and IL-7. Co-culture in the presence of these
cytokines individually or in combination increased total T cell ex-
pansion by 2–6 fold. Further, within 9 days of culture, cytokine-sup-
plemented CTLs had enhanced reactivity (measured by IFNg
ELIspot) against multiple immunodominant and subdominant viral
epitopes from EBV, CMV, and Adv. For example, Adv specificity in
the trivirus CTL detected responses against 5.25 hexon-peptide
pools (range 4–12) vs 1.5 pools (range 0–4) in ‘‘standard’’ CTL
from the same donors (n 5 6). Reactivity to CMV-pp65 was also
broader (10 pools (range 8–15) vs 4 (range 4–5). Anti-viral specific-
ities were sustained over multiple rounds of in vitro stimulation,
and the CTLs were cytolytic in chromium release and co-culture as-
says. In contrast, standard CTLs were only cytolytic against immu-
nodominant antigens. To date, addition of these cytokines has
allowed us to produce single cell lines containing effector cells spe-
cific for multiple epitopes in EBV, CMV, Adv, and BK antigens.
This technology will allow us to produce a single T cell product
which can safely protect against a wide range of pathogens simulta-
neously.375
EXPANSION OF REGULATORY T CELLS WITH ULTRA LOW-DOSE IL-2
AFTER ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION
Kennedy-Nasser, A.A., Ku, S., Chaiyarat, W., Foster, A., Savoldo, B.,
Yvon, E., Leung, K.S., Carrum, G., Kamble, R.T., Heslop, H.E.,
Brenner, M.K., Krance, R.A., Bollard, C.M. Baylor College of Medicine,
Texas Children’s Hospital and the Methodist Hospital, Houston, TX
CD41 CD251 FoxP31 regulatory T cells (Tregs) are of increas-
ing interest in hematopoietic stem cell transplantation (HSCT)
since they may help prevent graft-versus-host disease (GvHD). Mu-
rine models demonstrate that infusion of donor-derived Tregs to
HSCT recipient mice can prevent GvHD by suppressing alloreac-
tive T cell responses, while human recipients of allografts with low
Treg numbers have increased rates of GvHD. We and others have
previously given low-dose IL-2 to HSCT recipients in an attempt
to enhance antitumor immunity. Although no definitive antitumor
effects were observed, the patients were noted to have low rates of
GvHD. Retrospectively, it has been demonstrated that patients who
received IL-2 therapy had higher levels of FoxP31 T cells (i.e.,
Tregs) than controls, suggesting that IL-2 preferentially expands
Tregs in vivo, thereby preventing GvHD. We have therefore initi-
ated a phase I/II clinical trial to evaluate the efficacy and toxicity of
low-dose IL-2 injections following allogeneic HSCT. The intent is
to promote Treg expansion in vivo and prevent acute GvHD. Thus
far, 5 patients who received a HSCT for hematologic malignancies
have been treated with ultra low-dose IL-2 (100,000 to 200,000
units/m2 subcutaneously three times weekly) beginning day 17 to
day 128 after HSCT, for 6 to 12 weeks. Median age at time of
transplant was 21 years (range, 9 to 56 years). Two patients received
matched sibling donor transplants and three received alternative
donor transplants with Campath 1-H for in vivo T-cell depletion.
Flow cytometric analysis of blood from all patients demonstrated
a rise in the percentage of CD41 CD251 FoxP31 Tregs by 6 weeks
following initiation of IL-2 therapy with mean of 4.7% (range, 0 to
9.8%) pre IL-2 to a mean of 17.7% (range, 7.8 to 31.1%) after IL-2
treatment. Functional analyses of these CD41 CD25bright cells
showed suppression of thymidine uptake in mixed lymphocyte cul-
tures. No grade 3 or 4 toxicities occurred while on IL-2. No patient
developed . grade I acute GvHD. One patient who did not com-
plete the full 12 weeks of IL-2 therapy developed extensive, chronic
GvHD two months after stopping IL-2. In conclusion, low-dose
IL-2 is relatively well tolerated and may expand a CD41 CD251
FoxP31 Treg population in vivo. Their effects on GvHD and re-
lapse remain to be determined.376
RECOVERY OF IMMUNE CELL SUBSETS POSTTRANSPLANT IS ASSOCI-
ATED WITH INFECTION RISK BUT NOT SURVIVAL, RELAPSE OR NON-
RELAPSE MORTALITY
Geddes, M.1, Barry, S.2, Michael, B.2, Storek, J.1 1University of Calgary,
Calgary, AB, Canada; 2Fred Hutchinson Cancer Center, Seattle, WA
Background: Late recovery of total lymphocyte, CD4 T cell,
CD8 T cell, B cell or monocyte counts post transplant has been as-
sociated with poor transplant outcomes, including infections, in
some but not all studies involving relatively small numbers of pa-
tients. We set out to determine whether transplant outcomes could
be predicted from immune cell subset counts in a relatively large
group of patients (n 5 98) with long follow up (4 1⁄2 years).
Methods: In recipients of matched sibling myeloablative trans-
plant performed in 1996–2000 we prospectively measured the fol-
lowing immune subsets at day 30, 80, 180 and 365: total B cells,
IgD1 (naive) B cells, IgD- (memory) B cells, CD41 T cells,
CD81 T cells, CD41CD81 cells, CD4-CD8- T cells, CD281
(costimulation-competent) or CD28- CD4 or CD8 T cells, naı¨ve
(CD45RAhigh) or memory (CD45RAlow/neg) CD4 T cells, naı¨ve
(CD11alow) or memory (CD11ahigh) CD8 T cells, NK cells and
monocytes. Outcomes determined from a retrospective chart review
included total, definite (microbiologically documented), bacterial,
fungal, viral, HSV, VZV, and CMV infections in the intervals of
days 30–80, 81–180, 181–365, and .365 post transplant, as well as
overall survival, relapse, non-relapse mortality and fatal infection.
